| dc.contributor.author | Vander Heiden, Matthew G. | |
| dc.date.accessioned | 2013-01-08T14:38:57Z | |
| dc.date.available | 2013-01-08T14:38:57Z | |
| dc.date.issued | 2011-09 | |
| dc.identifier.issn | 1474-1784 | |
| dc.identifier.uri | http://hdl.handle.net/1721.1/76182 | |
| dc.description.abstract | Genetic events in cancer activate signalling pathways that alter cell metabolism. Clinical evidence has linked cell metabolism with cancer outcomes. Together, these observations have raised interest in targeting metabolic enzymes for cancer therapy, but they have also raised concerns that these therapies would have unacceptable effects on normal cells. However, some of the first cancer therapies that were developed target the specific metabolic needs of cancer cells and remain effective agents in the clinic today. Research into how changes in cell metabolism promote tumour growth has accelerated in recent years. This has refocused efforts to target metabolic dependencies of cancer cells as a selective anticancer strategy. | en_US |
| dc.description.sponsorship | Burroughs Wellcome Fund | en_US |
| dc.description.sponsorship | Smith Family Foundation | en_US |
| dc.description.sponsorship | Starr Cancer Consortium | en_US |
| dc.description.sponsorship | Damon Runyon Cancer Research Foundation | en_US |
| dc.description.sponsorship | National Institutes of Health (U.S.) | en_US |
| dc.language.iso | en_US | |
| dc.publisher | Nature Publishing Group | en_US |
| dc.relation.isversionof | http://dx.doi.org/10.1038/nrd3504 | en_US |
| dc.rights | Creative Commons Attribution-Noncommercial-Share Alike 3.0 | en_US |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/3.0/ | en_US |
| dc.source | Vander Heiden via Courtney Crummett | en_US |
| dc.title | Targeting cancer metabolism: a therapeutic window opens | en_US |
| dc.type | Article | en_US |
| dc.identifier.citation | Vander Heiden, Matthew G. “Targeting Cancer Metabolism: a Therapeutic Window Opens.” Nature Reviews Drug Discovery 10.9 (2011): 671–684. | en_US |
| dc.contributor.department | Massachusetts Institute of Technology. Department of Biology | en_US |
| dc.contributor.approver | Vander Heiden, Matthew | |
| dc.contributor.mitauthor | Vander Heiden, Matthew G. | |
| dc.relation.journal | Nature Reviews Drug Discovery | en_US |
| dc.eprint.version | Author's final manuscript | en_US |
| dc.type.uri | http://purl.org/eprint/type/JournalArticle | en_US |
| eprint.status | http://purl.org/eprint/status/PeerReviewed | en_US |
| dspace.orderedauthors | Vander Heiden, Matthew G. | en |
| dc.identifier.orcid | https://orcid.org/0000-0002-6702-4192 | |
| mit.license | OPEN_ACCESS_POLICY | en_US |
| mit.metadata.status | Complete | |